Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18509855 | 1.00 | NAMPT (0.53) | NAMPTLMNAMMP2MMP9ALDH1A1 | |
| SCHEMBL379486 | 1.00 | NAMPT (0.53) | NAMPTLMNAMMP2MMP9ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5087159 | 0.99 | NAMPT (0.52) | NAMPTLMNAMMP2MMP9ALDH1A1 | |
| Bromide SCHEMBL11455325 | 0.99 | NAMPT (0.52) | NAMPTLMNAMMP2MMP9ALDH1A1 | |
| Hydrochloric Acid SCHEMBL20214289 | 0.99 | NAMPT (0.52) | NAMPTLMNAMMP2MMP9ALDH1A1 | |
| SCHEMBL4953664 | 0.96 | NAMPT (0.49) | NAMPTLMNAMMP2MMP9ALDH1A1 | |
| SCHEMBL4953654 | 0.96 | NAMPT (0.49) | NAMPTLMNAMMP2MMP9ALDH1A1 | |
| SCHEMBL5172065 | 0.89 | F2 (0.51) | NAMPTLMNAMMP2MMP9ALDH1A1 | |
| Glycyl Proline SCHEMBL28466633 | 0.86 | F2 (0.48) | LMNAMMP2MMP9ALDH1A1EPHX2 | |
| SCHEMBL28579566 | 0.86 | LMNA (0.48) | LMNAMMP2MMP9ALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111500672-B | Glycylproline dipeptide aminopeptidase determination kit with high analysis sensitivity and preparation method and application thereof | 中科梅奥(山东)医学检验有限公司 | 2021-08-24 | — | — | CN | disclosed |
| US-10947290-B2 | Method of stabilizing a bioactive peptide against protease hydrolysis | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-03-16 | — | — | US | disclosed |
| CN-111778312-A | Kit for determining glycylproline dipeptide aminopeptidase in serum | 迪瑞医疗科技股份有限公司 | 2020-10-16 | — | — | CN | disclosed |
| CN-111778312-A | Kit for determining glycylproline dipeptide aminopeptidase in serum | 迪瑞医疗科技股份有限公司 | 2020-10-16 | — | — | CN | disclosed |
| CN-111500672-A | Glycylproline dipeptide aminopeptidase determination kit with high analysis sensitivity and preparation method and application thereof | 中科梅奥(山东)医学检验有限公司 | 2020-08-07 | — | — | CN | disclosed |
| CN-111172234-A | Glycylproline dipeptide aminopeptidase determination kit | 浙江夸克生物科技有限公司 | 2020-05-19 | — | — | CN | disclosed |
| US-20190085044-A1 | NOVEL THIOAMIDE-MODIFIED PEPTIDES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2019-03-21 | — | — | US | disclosed |
| US-8236756-B2 | HIV protease inhibitory compounds with ameliorated solubility and/or bioavailability; conjugates of therapeutic compound and a peptide wherein the conjugate is cleavable by dipeptidyl-peptidases | Consejo Superior de Investigaciones Clentificas (CSIC) (ES) | 2012-08-07 | — | — | US | disclosed |
| US-7625939-B2 | Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase IV inhibitors | PROBIODRUG AG (DE) | 2009-12-01 | — | — | US | disclosed |
| US-7608577-B2 | Peptidyl ketones as inhibitors of DPIV | OSI PHARMACEUTICALS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20030162820-A1 | Glutaminyl based DPIV inhibitors | PROSIDION LIMITED (GB) | 2003-08-28 | — | — | US | disclosed |
| US-20030148961-A1 | Peptidyl ketones as inhibitors of DPIV | PROSIDION LIMITED (GB) | 2003-08-07 | — | — | US | disclosed |
| US-20030130199-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | PROBIODRUG (DE) | 2003-07-10 | — | — | US | disclosed |
| US-20030125304-A1 | Substituted amino ketone compounds | PROSIDION LIMITED (GB) | 2003-07-03 | — | — | US | disclosed |
| US-20030119750-A1 | Use of dipeptidyl peptidase IV inhibitors | PROBIODRUG (DE) | 2003-06-26 | — | — | US | disclosed |
| WO-2003040174-A2 | SUBSTITUTED AMINO KETONE COMPOUNDS | PROBIODRUG AG (DE) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003033524-A2 | PEPTIDYL KETONES AS INHIBITORS OF DPIV | PROBIODRUG AG (DE) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003015775-A1 | NEW DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES FOR LOWERING BLOOD PRESSURE LEVELS | PROBIODRUG AG (DE) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003002596-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002595-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES AS ANTI-CANCER AGENTS | PROBIODRUG AG (DE) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030148961-A1 | Peptidyl ketones as inhibitors of DPIV | GLS, SLC5A1, BCKDK | NAMPT 2925/4885LMNA 3536/4885MMP2 1826/4885 |
| US-20190085044-A1 | NOVEL THIOAMIDE-MODIFIED PEPTIDES AND USES THEREOF | PTMS, IAPP, LNPEP | NAMPT 313/4885LMNA 4440/4885MMP2 3753/4885 |
| US-10947290-B2 | Method of stabilizing a bioactive peptide against protease hydrolysis | PREP, PEPD, VIP | NAMPT 663/4885LMNA 2415/4885MMP2 136/4885 |
| US-20030125304-A1 | Substituted amino ketone compounds | SLC5A1, GLS, GPR119 | NAMPT 2153/4885LMNA 270/4885MMP2 4711/4885 |
| US-20030130199-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | DPP4, DPP3, DNPEP | NAMPT 1596/4885LMNA 4845/4885MMP2 9/4885 |
| US-20030119750-A1 | Use of dipeptidyl peptidase IV inhibitors | DPP4, DPP3, DPP7 | NAMPT 2223/4885LMNA 4223/4885MMP2 28/4885 |
| US-20030162820-A1 | Glutaminyl based DPIV inhibitors | GLS, SLC7A11, GLS2 | NAMPT 825/4885LMNA 4880/4885MMP2 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.